Opus Genetics IRD EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Opus Genetics’s reported figures.
Based on trailing twelve months.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's EBITDA margin?
- Opus Genetics (IRD) reported EBITDA margin of -358.7% in Q1 2026.
- How has Opus Genetics's EBITDA margin changed year-over-year?
- Opus Genetics's EBITDA margin increased by 23.8% year-over-year, from -470.8% to -358.7%.
- What is the long-term trend for Opus Genetics's EBITDA margin?
- Over 3 years (2022 to 2025), Opus Genetics's EBITDA margin has grown at a 81.1% compound annual growth rate (CAGR), from 45.7% to -271.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.